Asio Capital LLC Has $5.65 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Asio Capital LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,590 shares of the company’s stock after buying an additional 1,049 shares during the quarter. Johnson & Johnson accounts for 1.8% of Asio Capital LLC’s investment portfolio, making the stock its 12th largest holding. Asio Capital LLC’s holdings in Johnson & Johnson were worth $5,651,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Taylor & Morgan Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after acquiring an additional 57 shares in the last quarter. Red Wave Investments LLC raised its holdings in shares of Johnson & Johnson by 2.0% in the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after acquiring an additional 59 shares in the last quarter. Argus Investors Counsel Inc. raised its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after acquiring an additional 61 shares in the last quarter. Alta Capital Management LLC raised its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after acquiring an additional 61 shares in the last quarter. Finally, Paces Ferry Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after acquiring an additional 62 shares in the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.3 %

JNJ opened at $173.43 on Monday. The stock has a market cap of $453.43 billion, a PE ratio of 24.15, a PEG ratio of 3.28 and a beta of 0.56. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The business has a 50 day moving average of $176.32 and a 200-day moving average of $171.47. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.60 EPS. Equities research analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is 62.95%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,707,775. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 300,750 shares of company stock worth $52,311,677. 0.35% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on JNJ. Morgan Stanley reduced their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Atlantic Securities reduced their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Barclays started coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Finally, Credit Suisse Group started coverage on Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $182.42.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.